QuidelOrtho (QDEL) Securities Fraud Class Action Filed After QDEL Reports Disastrous Q4 2023 Results, Terminates CEO, Withdraws FDA Submission - Hagens Berman

Hagens Berman, National Trial Attorneys, Encourages QDEL Investors Who Suffered Substantial Losses to Contact its Attorneys

SAN FRANCISCO - Hagens Berman urges QuidelOrtho Corporation (NASDAQ: QDEL) investors who suffered substantial losses to submit your losses now.  

Class Period: Feb. 18, 2022 – Apr. 1, 2024

Lead Plaintiff Deadline: June 11, 2024

Visit: www.hbsslaw.com/investor-fraud/QDEL

Contact An Attorney Now: [email protected], 844-916-0895

QuidelOrtho Corporation (NASDAQ: QDEL) Securities Class Action:

The litigation is focused on the propriety of QuidelOrtho’s past assurances about its preparedness to maintain a stable high margin revenue stream from its respiratory business in the face of the COVID-19 pandemic becoming an endemic and about its FDA submission for its purported “next flagship product” (the “Savanna RVP4 Test”) being “on track.”

The complaint alleges QuidelOrtho misled investors by making statements that were false and misleading because it knew or deliberately disregarded that: (1) it sold more COVID-19 tests to its distributors and pharmacy chain customers than they could resell to healthcare providers and end customers; (2) excess inventories of COVID-19 tests existed throughout the supply chain; (3) as a result, its distributor and pharmacy chain customers were poised to significantly reduce their COVID-19 test orders; and (4) undisclosed problems created a heightened risk that the Savanna RVP4 Test would experience a delayed commercial launch in the U.S..

Investors began to learn the truth on Feb. 13 2024, when QuidelOrtho announced disastrous Q4 and FY 2023 financial results. Among other things, the company’s Adjusted EPS was 46% below the midpoint of Wall Street analysts’ expectations which the company blamed on lower endemic COVID-19 revenues during the quarter from distributor destocking. In addition, QuidelOrtho’s Adjusted EBITDA came in 28% below the analysts’ consensus expectations and the company slashed its 2024 endemic COVID-19 revenue guidance to $200 million.

Then, on Feb. 21, 2024, QuidelOrtho announced that its Board terminated President and CEO Douglas Bryant, with one analyst commenting “[f]ollowing last week’s 2024 guidance debacle and the ensuing calls from many investors advocating for a change in management, we understand why the [B]oard made this move.”

Most recently, on Apr. 2, 2024, QuidelOrtho announced that it withdrew its submission for the Savanna RVP4 Test because recent data failed to meet expectations.

Since Feb. 13, 2024, the price of QuidelOrtho shares has fallen $24.59, or nearly 37%, wiping out about $1.6 billion of shareholder value.

“We are investigating whether QuidelOrtho may have engaged in improper channel-stuffing and about the likelihood of FDA approval for the Savanna test,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you invested in QuidelOrtho and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to frequently asked questions about the QuidelOrtho case and our investigation, read more »

Whistleblowers: Persons with non-public information regarding QuidelOrtho should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

# # #

About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation law firm focusing on corporate accountability through class-action law. The firm is home to a robust securities litigation practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and fraud. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw

Hagens Berman purchases advertisements on search engines, social media sites and other websites. Transmission of the information contained or available through this website is not intended to create, and receipt does not constitute, an attorney-client relationship. If you seek legal advice or representation by Hagens Berman, you must first enter a formal agreement. All information contained in any transmission is confidential and Hagens Berman agrees to protect information against unauthorized use, publication or disclosure. This site is regulated by the Washington Rules of Professional Conduct.